MCID: UTR043
MIFTS: 51

Uterine Sarcoma

Categories: Cancer diseases, Rare diseases

Aliases & Classifications for Uterine Sarcoma

MalaCards integrated aliases for Uterine Sarcoma:

Name: Uterine Sarcoma 54 56 17
Uterine Corpus Sarcoma 74
Sarcoma of the Uterus 54

Classifications:



External Ids:

UMLS 74 C0338113

Summaries for Uterine Sarcoma

MalaCards based summary : Uterine Sarcoma, also known as uterine corpus sarcoma, is related to soft tissue sarcoma and carcinosarcoma. An important gene associated with Uterine Sarcoma is ABCB1 (ATP Binding Cassette Subfamily B Member 1), and among its related pathways/superpathways are PI3K-Akt signaling pathway and Endometrial cancer. The drugs Ifosfamide and Cisplatin have been mentioned in the context of this disorder. Affiliated tissues include uterus, smooth muscle and brain, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 77 The uterine sarcomas form a group of malignant tumors that arises from the smooth muscle or connective... more...

Related Diseases for Uterine Sarcoma

Diseases related to Uterine Sarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 144)
# Related Disease Score Top Affiliating Genes
1 soft tissue sarcoma 30.2 ABCB1 MDM2 TP53
2 carcinosarcoma 29.9 DES KIT MME TP53
3 sarcoma, synovial 29.8 DES KIT MDM2
4 rhabdoid cancer 29.7 MB SMARCB1 TP53 WT1
5 uterine carcinosarcoma 29.4 KIT MME TP53
6 leiomyoma 29.3 CYP19A1 DES ESR1 KIT MME
7 ewing sarcoma 28.9 CDK2 DES KIT MDM2 PDGFRB TP53
8 leiomyosarcoma 28.9 DES KIT MB MDM2 PDGFRB TP53
9 adenosarcoma 28.3 DES ESR1 KIT MB MME TP53
10 breast cancer 27.9 ABCB1 ABCC1 CCND2 CDK2 CYP19A1 ESR1
11 endometrial stromal sarcoma 27.8 CYP19A1 DES ESR1 KIT MB MME
12 sarcoma 11.0
13 cerebellar angioblastoma 10.4 TP53 WT1
14 testicular gonadoblastoma 10.4 KIT WT1
15 spindle cell sarcoma 10.3
16 cervix carcinoma 10.3 ABCB1 ABCC1 TP53
17 uterine inversion 10.3
18 myeloid sarcoma 10.3
19 microsporidiosis 10.3 ABCB1 ABCC1
20 cellular neurofibroma 10.3 PDGFRB TP53
21 ring chromosome 7 10.3 MDM2 TP53
22 zika virus infection 10.3 MDM2 TP53
23 ovarian fibrothecoma 10.3 DES KIT
24 extraosseous osteosarcoma 10.2 DCK MDM2
25 core binding factor acute myeloid leukemia 10.2 KIT MVP WT1
26 retroperitoneal sarcoma 10.2 MDM2 SMARCB1
27 gallbladder sarcoma 10.2 DES KIT
28 proliferative fasciitis 10.2 MB SMARCB1
29 kidney sarcoma 10.2 MB WT1
30 hypereosinophilic syndrome, idiopathic 10.2 KIT PDGFRB WT1
31 chronic eosinophilic leukemia 10.2 KIT PDGFRB WT1
32 actinic cheilitis 10.2 MDM2 TP53
33 kidney rhabdoid cancer 10.2 MB SMARCB1 WT1
34 female reproductive endometrioid cancer 10.2 ESR1 TP53 WT1
35 giant cell myocarditis 10.1 DES MB
36 small cell sarcoma 10.1 MDM2 SMARCB1 TP53
37 ocular cancer 10.1 CDK2 MDM2 TP53
38 neurilemmoma 10.1 DES KIT SMARCB1
39 malignant ovarian surface epithelial-stromal neoplasm 10.1 ESR1 TP53 WT1
40 ovary epithelial cancer 10.1 ESR1 TP53 WT1
41 malignant triton tumor 10.1 DES MB
42 peritoneal benign neoplasm 10.1 ESR1 KIT WT1
43 diffuse peritoneal leiomyomatosis 10.1 ESR1 KIT WT1
44 skin melanoma 10.1 MCAM MDM2 TP53
45 small cell cancer of the lung 10.1 ABCB1 ABCC1 KIT TP53
46 botryoid rhabdomyosarcoma 10.1 DES MB
47 angiomyoma 10.1 CDK2 KIT MB
48 rhabdoid tumor predisposition syndrome 1 10.1 DES SMARCB1 TP53 WT1
49 alveolar soft part sarcoma 10.1
50 spindle cell lipoma 10.1 DES MDM2

Graphical network of the top 20 diseases related to Uterine Sarcoma:



Diseases related to Uterine Sarcoma

Symptoms & Phenotypes for Uterine Sarcoma

GenomeRNAi Phenotypes related to Uterine Sarcoma according to GeneCards Suite gene sharing:

27 (show all 11)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00107-A-1 10.02 DCK
2 Decreased viability GR00221-A-1 10.02 DCK ESR1 KIT PDGFRB SMARCB1
3 Decreased viability GR00221-A-2 10.02 DCK ESR1 SMARCB1
4 Decreased viability GR00221-A-3 10.02 PDGFRB SMARCB1
5 Decreased viability GR00221-A-4 10.02 DCK ESR1 PDGFRB
6 Decreased viability GR00240-S-1 10.02 DCK
7 Decreased viability GR00301-A 10.02 KIT
8 Decreased viability GR00342-S-1 10.02 PDGFRB
9 Decreased viability GR00381-A-1 10.02 SMARCB1
10 Decreased viability GR00402-S-2 10.02 DCK ESR1 KIT PDGFRB SMARCB1
11 Increased cell death HMECs cells GR00103-A-0 9.1 CCND2 CDK2 DCK MDM2 PDGFRB TP53

MGI Mouse Phenotypes related to Uterine Sarcoma:

47 (show all 21)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.44 ABCB1 CCND2 CDK2 CYP19A1 DES ESR1
2 homeostasis/metabolism MP:0005376 10.43 ABCB1 ABCC1 CCND2 CDK2 CYP19A1 DES
3 behavior/neurological MP:0005386 10.41 ABCB1 CCND2 CYP19A1 DES ESR1 KIT
4 hematopoietic system MP:0005397 10.41 ABCB1 ABCC1 CCND2 CDK2 CYP19A1 DCK
5 immune system MP:0005387 10.39 ABCB1 ABCC1 CCND2 CDK2 CYP19A1 DCK
6 cellular MP:0005384 10.36 CDK2 CYP19A1 DCK DES ESR1 KIT
7 endocrine/exocrine gland MP:0005379 10.34 ABCB1 CCND2 CDK2 CYP19A1 DCK ESR1
8 growth/size/body region MP:0005378 10.33 ABCB1 CDK2 CYP19A1 ESR1 KIT MB
9 mortality/aging MP:0010768 10.3 ABCB1 ABCC1 CCND2 CDK2 DES ESR1
10 embryo MP:0005380 10.22 CDK2 ESR1 KIT MB MDM2 PDGFRB
11 liver/biliary system MP:0005370 10.22 ABCB1 CCND2 CDK2 CYP19A1 ESR1 KIT
12 digestive/alimentary MP:0005381 10.18 ABCB1 CYP19A1 ESR1 KIT MDM2 PDGFRB
13 muscle MP:0005369 10.17 CDK2 CYP19A1 DES ESR1 KIT MB
14 integument MP:0010771 10.15 CDK2 CYP19A1 ESR1 KIT MDM2 MME
15 nervous system MP:0003631 10.15 ABCB1 ABCC1 CCND2 CYP19A1 ESR1 KIT
16 neoplasm MP:0002006 9.95 CDK2 ESR1 KIT MDM2 SMARCB1 TP53
17 normal MP:0002873 9.91 CYP19A1 DCK ESR1 KIT MDM2 MVP
18 no phenotypic analysis MP:0003012 9.87 ABCB1 ESR1 KIT MCAM MDM2 TP53
19 reproductive system MP:0005389 9.73 ABCB1 CCND2 CDK2 CYP19A1 ESR1 KIT
20 renal/urinary system MP:0005367 9.7 CYP19A1 ESR1 KIT MDM2 PDGFRB TP53
21 vision/eye MP:0005391 9.23 CCND2 CDK2 CYP19A1 KIT NAV2 PDGFRB

Drugs & Therapeutics for Uterine Sarcoma

Drugs for Uterine Sarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 177)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ifosfamide Approved Phase 3,Phase 2,Phase 1,Early Phase 1 3778-73-2 3690
2
Cisplatin Approved Phase 3,Phase 2 15663-27-1 441203 84093 2767
3
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1,Early Phase 1 23214-92-8 31703
4
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Not Applicable 33069-62-4 36314
5
Docetaxel Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 114977-28-5 148124
6
Gemcitabine Approved Phase 3,Phase 2,Phase 1,Not Applicable 95058-81-4 60750
7
Carboplatin Approved Phase 3,Phase 2,Phase 1,Not Applicable 41575-94-4 38904 10339178 498142
8
Mechlorethamine Approved, Investigational Phase 3,Phase 2,Phase 1 51-75-2 4033
9
Lenograstim Approved, Investigational Phase 3,Phase 2,Phase 1 135968-09-1
10
Mesna Approved, Investigational Phase 3 3375-50-6 598
11
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
12
Sargramostim Approved, Investigational Phase 3,Phase 2,Phase 1 123774-72-1, 83869-56-1
13
Bevacizumab Approved, Investigational Phase 3 216974-75-3
14
Cyproheptadine Approved Phase 3 129-03-3 2913
15
Histamine Approved, Investigational Phase 3 51-45-6 774
16
Dehydroepiandrosterone Approved, Investigational, Nutraceutical Phase 3 53-43-0 9860744
17
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1,Early Phase 1 31703
18 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
19
Isophosphamide mustard Phase 3,Phase 2,Phase 1,Early Phase 1 0
20 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
21 Antineoplastic Agents, Alkylating Phase 3,Phase 2,Phase 1,Early Phase 1
22 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1,Early Phase 1
23 Alkylating Agents Phase 3,Phase 2,Phase 1,Early Phase 1
24 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1,Early Phase 1
25 Albumin-Bound Paclitaxel Phase 3,Phase 2,Not Applicable
26 Antimitotic Agents Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
27 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
28 Cola Phase 3,Phase 1,Not Applicable,Early Phase 1
29 Immunologic Factors Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
30 Immunosuppressive Agents Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
31 Antimetabolites Phase 3,Phase 2,Phase 1,Not Applicable
32 Anti-Infective Agents Phase 3,Phase 2,Phase 1,Not Applicable
33 Antiviral Agents Phase 3,Phase 2,Phase 1,Not Applicable
34 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1,Not Applicable
35 Angiogenesis Inhibitors Phase 3,Phase 2,Phase 1
36 Angiogenesis Modulating Agents Phase 3,Phase 2,Phase 1
37 Analgesics Phase 3,Phase 2,Phase 1,Not Applicable
38 Liver Extracts Phase 3,Phase 1,Phase 2,Early Phase 1
39 Adjuvants, Anesthesia Phase 3
40 Anesthetics, General Phase 3
41 Analgesics, Opioid Phase 3
42 Peripheral Nervous System Agents Phase 3,Phase 2,Phase 1,Not Applicable
43 Central Nervous System Depressants Phase 3
44 Anesthetics Phase 3
45 Anesthetics, Intravenous Phase 3
46 Narcotics Phase 3
47 DHEA (Dehydroepiandrosterone) Phase 3
48 Adjuvants, Immunologic Phase 3,Phase 2,Phase 1
49 Antineoplastic Agents, Immunological Phase 3,Phase 2,Not Applicable
50 Mitogens Phase 3,Phase 2

Interventional clinical trials:

(show top 50) (show all 124)
# Name Status NCT ID Phase Drugs
1 The Addition of Polychemotherapy to Adjuvant Radiotherapy in the Treatment of Non-Metastatic Uterine Sarcomas Unknown status NCT00162721 Phase 3 doxorubicin, ifosfamide, cisplatin
2 Hyperbaric Oxygen Therapy in Treating Long-Term Gastrointestinal Adverse Effects Caused by Radiation Therapy in Patients With Pelvic Cancer Unknown status NCT01087268 Phase 3
3 Laparoscopic Surgery or Standard Surgery in Treating Patients With Endometrial Cancer or Cancer of the Uterus Completed NCT00002706 Phase 3
4 Radiation Therapy or No Further Treatment Following Surgery in Treating Patients With Cancer of the Uterus Completed NCT00002459 Phase 3
5 Ifosfamide With or Without Paclitaxel in Treating Patients With Advanced, Refractory, or Recurrent Cancer of the Uterus Completed NCT00003128 Phase 3 ifosfamide;paclitaxel
6 Radiation Therapy Compared With Combination Chemotherapy in Treating Patients With Cancer of the Uterus Completed NCT00002546 Phase 3 cisplatin;ifosfamide
7 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
8 Surgery With or Without Chemotherapy in Treating Patients With Soft Tissue Sarcoma Completed NCT00002641 Phase 3 doxorubicin hydrochloride;ifosfamide;isolated perfusion
9 Surgery With or Without Combination Chemotherapy in Treating Patients With Lung Metastases From Soft Tissue Sarcoma Completed NCT00002764 Phase 3 doxorubicin hydrochloride;ifosfamide
10 Ifosfamide or Doxorubicin in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00003212 Phase 3 doxorubicin hydrochloride;ifosfamide
11 Prasterone (Dehydroepiandrosterone) in Treating Postmenopausal Cancer Survivors With Vaginal Symptoms Completed NCT01376349 Phase 3 prasterone
12 Short Course Vaginal Cuff Brachytherapy in Treating Patients With Stage I-II Endometrial Cancer Recruiting NCT03422198 Phase 3
13 Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by Surgery Active, not recruiting NCT01533207 Phase 3 Docetaxel;Doxorubicin Hydrochloride;Gemcitabine Hydrochloride
14 Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer Active, not recruiting NCT00954174 Phase 3 Carboplatin;Ifosfamide;Paclitaxel
15 Gemcitabine Hydrochloride and Docetaxel With or Without Bevacizumab in Treating Patients With Advanced or Recurrent Uterine Leiomyosarcoma Terminated NCT01012297 Phase 3 Docetaxel;Gemcitabine Hydrochloride
16 Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
17 Continuing vs Intermittent Trabectedin in Patients With Advanced Soft Tissue Sarcoma Unknown status NCT01303094 Phase 2 Trabectedin
18 Phase 1-2 Study of Onapristone in Patients With Progesterone Receptor Expressing Cancers Unknown status NCT02052128 Phase 1, Phase 2 onapristone
19 Temozolomide and Thalidomide in Treating Patients With Metastatic, Locally Advanced, or Unresectable Leiomyosarcoma Unknown status NCT00033709 Phase 2 temozolomide;thalidomide
20 Brostallicin or Doxorubicin as First-Line Therapy in Treating Patients With Relapsed, Refractory, or Metastatic Soft Tissue Sarcoma Unknown status NCT00410462 Phase 2 brostallicin;doxorubicin hydrochloride
21 Temozolomide in Treating Patients With Advanced Soft Tissue Sarcoma Unknown status NCT00003718 Phase 2 temozolomide
22 Nutritional Supplements in Improving Quality of Life During First-Line Chemotherapy in Patients With Metastatic Gynecological Cancer Unknown status NCT00905658 Phase 2
23 Chemotherapy in Treating Patients With Sarcoma of the Uterus Completed NCT00005643 Phase 2 pegylated liposomal doxorubicin hydrochloride
24 Sunitinib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus Completed NCT00378911 Phase 2 sunitinib malate
25 Imatinib Mesylate in Treating Patients With Recurrent or Persistent Uterine Cancer Completed NCT00075400 Phase 2 imatinib mesylate
26 Multicenter Trial With PegLiposomal Doxorubicin and Carboplatin Combination Chemotherapy in Gynecological Sarcomas and Mixed Epithelial-Mesenchymal Tumors Completed NCT00815945 Phase 2 PegLiposomal Doxorubicin;Carboplatin
27 Sorafenib in Treating Patients With Advanced or Recurrent Uterine Cancer Completed NCT00238121 Phase 2 sorafenib tosylate
28 Alisertib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus Completed NCT01637961 Phase 2 Alisertib
29 Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer Completed NCT01247571 Phase 2 Pazopanib Hydrochloride
30 Ixabepilone in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus Previously Treated With Chemotherapy Completed NCT01220609 Phase 2 Ixabepilone
31 Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer Completed NCT01168232 Phase 2 Ixabepilone
32 Gemcitabine and Docetaxel in Treating Patients With Recurrent or Persistent Uterine Cancer Completed NCT00114218 Phase 2 Gemcitabine Hydrochloride;Docetaxel
33 Combination Chemotherapy and Filgrastim or Pegfilgrastim in Treating Patients With Recurrent or Persistent Cancer of the Uterus Completed NCT00031629 Phase 2 Docetaxel;Gemcitabine Hydrochloride
34 Thalidomide in Treating Patients With Recurrent or Persistent Carcinosarcoma of the Uterus Completed NCT00025506 Phase 2 Thalidomide
35 Thalidomide in Treating Patients With Recurrent or Persistent Cancer of the Uterus Completed NCT00025220 Phase 2 Thalidomide
36 Paclitaxel and Carboplatin in Treating Patients With Persistent or Recurrent Stage III or Stage IV Uterine Cancer Completed NCT00112489 Phase 2 carboplatin;paclitaxel
37 Docetaxel, Gemcitabine, and Filgrastim (G-CSF) or Pegfilgrastim in Treating Patients With Advanced, Persistent, or Recurrent Uterine Leiomyosarcoma Completed NCT00101127 Phase 2 docetaxel;gemcitabine hydrochloride
38 Trabectedin in Treating Patients With Advanced, Persistent, or Recurrent Leiomyosarcoma of the Uterus Completed NCT00379145 Phase 2 trabectedin
39 Dolastatin 10 in Treating Patients With Recurrent or Metastatic Soft Tissue Sarcoma Completed NCT00003778 Phase 2 dolastatin 10
40 Psychosexual Intervention in Patients With Stage I-III Gynecologic or Breast Cancer Completed NCT01764802 Phase 2
41 Therapeutic Angiotensin-(1-7) in Treating Patients With Metastatic Sarcoma That Cannot Be Removed By Surgery Completed NCT01553539 Phase 2 therapeutic angiotensin-(1-7)
42 Stereotactic Radiosurgery Using CyberKnife in Treating Women With Advanced or Recurrent Gynecological Malignancies Completed NCT01079832 Phase 2
43 AZD0530 in Treating Patients With Recurrent Locally Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00659360 Phase 2 saracatinib
44 Ziv-aflibercept in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gynecologic Soft Tissue Sarcoma Completed NCT00390234 Phase 2 ziv-aflibercept
45 Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma Completed NCT00245102 Phase 2 sorafenib tosylate
46 Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma Completed NCT01154452 Phase 1, Phase 2 Gamma-Secretase Inhibitor RO4929097;Vismodegib
47 Thalidomide in Treating Patients With Gynecologic Sarcomas Completed NCT00006005 Phase 2 thalidomide
48 Liposomal Doxorubicin and Carboplatin in Treating Patients With Gynecologic Cancer Completed NCT00032162 Phase 1, Phase 2 carboplatin;pegylated liposomal doxorubicin hydrochloride
49 Chemotherapy in Treating Patients With Advanced Sarcoma Completed NCT00002526 Phase 2 doxorubicin hydrochloride;ifosfamide
50 Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas Completed NCT00474994 Phase 2 sunitinib malate

Search NIH Clinical Center for Uterine Sarcoma

Genetic Tests for Uterine Sarcoma

Anatomical Context for Uterine Sarcoma

MalaCards organs/tissues related to Uterine Sarcoma:

42
Uterus, Smooth Muscle, Brain, Bone, Endothelial, Kidney, T Cells

Publications for Uterine Sarcoma

Articles related to Uterine Sarcoma:

(show top 50) (show all 302)
# Title Authors Year
1
Localized high grade endometrial stromal sarcoma and localized undifferentiated uterine sarcoma: a retrospective series of the French Sarcoma Group. ( 30772825 )
2019
2
Preoperative Differentiation of Uterine Sarcoma from Leiomyoma: Comparison of Three Models Based on Different Segmentation Volumes Using Radiomics. ( 30850967 )
2019
3
A multiparametric MRI-based machine learning to distinguish between uterine sarcoma and benign leiomyoma: comparison with 18F-FDG PET/CT. ( 30471748 )
2019
4
Resveratrol suppresses proliferation and induces apoptosis of uterine sarcoma cells by inhibiting the Wnt signaling pathway. ( 30867708 )
2019
5
A machine learning approach for distinguishing uterine sarcoma from leiomyomas based on perfusion weighted MRI parameters. ( 30599861 )
2019
6
NTRK Fusions Define a Novel Uterine Sarcoma Subtype With Features of Fibrosarcoma. ( 29553955 )
2018
7
Can the risks associated with uterine sarcoma morcellation really be prevented? Overview of the role of uterine morcellation in 2018. ( 29879489 )
2018
8
Treatment of Uterine Sarcoma with rAd-p53 (Gendicine) Followed by Chemotherapy: Clinical Study of TP53 Gene Therapy. ( 29281902 )
2018
9
SMARCA4-deficient undifferentiated uterine sarcoma (malignant rhabdoid tumor of the uterus): a clinicopathologic entity distinct from undifferentiated carcinoma. ( 29700418 )
2018
10
The impact of morcellation on survival outcomes of undiagnosed uterine sarcoma. ( 29892685 )
2018
11
RNA-sequencing identifies novel GREB1-NCOA2 fusion gene in a uterine sarcoma with the chromosomal translocation t(2;8)(p25;q13). ( 29218853 )
2018
12
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in seven patients with peritoneal sarcomatosis from uterine sarcoma. ( 29881584 )
2018
13
Rare case of undifferentiated uterine sarcoma with neuroectodermal differentiation and osteoclast-like giant cells. ( 29880181 )
2018
14
Clinical Characteristics Differentiating Uterine Sarcoma and Fibroids. ( 29398899 )
2018
15
Expression and prognostic value of lactate dehydrogenase-A and -D subunits in human uterine myoma and uterine sarcoma. ( 29620641 )
2018
16
Pazopanib monotherapy in the treatment of pretreated, metastatic uterine sarcoma: a single-center retrospective study. ( 29185261 )
2018
17
Efficacy of Hyperthermic Intraperitoneal Chemotherapy and Cytoreductive Surgery in the Treatment of Recurrent Uterine Sarcoma. ( 29975291 )
2018
18
Reducing the spread of occult uterine sarcoma at the time of minimally invasive gynecologic surgery. ( 29128980 )
2018
19
Uterine Sarcoma Presenting with Sepsis from <i>Clostridium perfringens</i> Endometritis in a Postmenopausal Woman. ( 29850320 )
2018
20
Utility of Clinical Parameters and Multiparametric MRI as Predictive Factors for Differentiating Uterine Sarcoma From Atypical Leiomyoma. ( 29422425 )
2018
21
Could miRNA Signatures be Useful for Predicting Uterine Sarcoma and Carcinosarcoma Prognosis and Treatment? ( 30200635 )
2018
22
Results of an internal audit on the survival of patients with uterine sarcoma. ( 30299262 )
2018
23
Uterine Sarcoma - Difficult to Diagnose, Hard to Treat. ( 30326471 )
2018
24
Correction to: Reply to ''Comments on ''Magnetic resonance imaging features of uterine sarcoma and mimickers''. ( 30328485 )
2018
25
Increased LDH5/LDH1 ratio in preoperative diagnosis of uterine sarcoma with inconclusive MRI and LDH total activity but suggestive CT scan: a case report. ( 30340636 )
2018
26
Hexane fraction of adlay (Coix lachryma-jobi L.) testa ethanolic extract inhibits human uterine sarcoma cancer cells growth and chemosensitizes human uterine sarcoma cells to doxorubicin. ( 30166110 )
2018
27
Reply to "Comments on "Magnetic resonance imaging features of uterine sarcoma and mimickers". ( 30255445 )
2018
28
Letter to the editor regarding the article "Magnetic resonance imaging features of uterine sarcoma and mimickers". ( 30267106 )
2018
29
Efficacy of PET/CT to exclude leiomyoma in patients with lesions suspicious for uterine sarcoma on MRI. ( 28805609 )
2017
30
Uterine sarcoma with ambiguous histomorphology: A case report. ( 28271093 )
2017
31
Cytotoxic effects of 15-deoxy-I912,14-prostaglandin J2 alone and in combination with dasatinib against uterine sarcoma in vitro. ( 28587364 )
2017
32
Undifferentiated Uterine Sarcoma: An Uncommon Case Report. ( 28511398 )
2017
33
18F-FDG/18F-FES standardized uptake value ratio determined using PET predicts prognosis in uterine sarcoma. ( 28186981 )
2017
34
Multi-institutional study of peritoneal sarcomatosis from uterine sarcoma treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. ( 28967566 )
2017
35
Neuron navigator-2 and cyclin D2 are new candidate prognostic markers in uterine sarcoma. ( 28643014 )
2017
36
Unsuspected Uterine Sarcoma in an Urban Hospital: Does Surgical Approach Matter? ( 29061369 )
2017
37
Optimizing Local Control in High-Grade Uterine Sarcoma: Adjuvant Vaginal Vault Brachytherapy as Part of a Multimodal Treatment. ( 28174295 )
2017
38
Elevated levels of serum MiR-152 and miR-24 in uterine sarcoma: potential for inducing autophagy via SIRT1 and deacetylated LC3. ( 28929922 )
2017
39
A Multicentre Retrospective Review of Clinical Characteristics of Uterine Sarcoma. ( 28729098 )
2017
40
Safety of ovarian preservation in premenopausal women with stage I uterine sarcoma. ( 28541635 )
2017
41
Uterine sarcoma - current perspectives. ( 28919822 )
2017
42
Does the patients age at cancer diagnosis affect microvessels density in uterine sarcoma tissues? ( 28397202 )
2017
43
Role of Lymphadenectomy for Uterine Sarcoma: A Meta-Analysis. ( 27668397 )
2017
44
Pulmonary Metastasis of Undifferentiated Uterine Sarcoma Forming Fluid-Containing Cyst. ( 28862061 )
2017
45
Uterine epithelioid leiomyosarcoma with c-kit expression and YWHAE gene rearrangement: a case report of a diagnostic pitfall of uterine sarcoma. ( 28288693 )
2017
46
Establishment and characterization of uterine sarcoma and carcinosarcoma patient-derived xenograft models. ( 28625393 )
2017
47
Magnetic resonance imaging features of uterine sarcoma and mimickers. ( 28246921 )
2017
48
Uterine Sarcoma: Clinical Presentation, Treatment and Survival Outcomes in Thailand. ( 27221849 )
2016
49
Uterine sarcoma Part I-Uterine leiomyosarcoma: The Topic Advisory Group systematic review. ( 27590365 )
2016
50
Uterine sarcoma part III-Targeted therapy: The Taiwan Association of Gynecology (TAG) systematic review. ( 27751406 )
2016

Variations for Uterine Sarcoma

Expression for Uterine Sarcoma

Search GEO for disease gene expression data for Uterine Sarcoma.

Pathways for Uterine Sarcoma

Pathways related to Uterine Sarcoma according to GeneCards Suite gene sharing:

(show all 33)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.89 CCND2 CDK2 KIT MDM2 PDGFRB TP53
2
Show member pathways
12.8 CDK2 KIT MDM2 PDGFRB TP53
3
Show member pathways
12.58 ABCB1 CDK2 ESR1 KIT SMARCB1 TP53
4
Show member pathways
12.53 CCND2 CDK2 ESR1 MDM2 PDGFRB TP53
5 12.42 CCND2 CDK2 ESR1 KIT MDM2 PDGFRB
6 12.41 ABCB1 ABCC1 CYP19A1 MB PGRMC1
7
Show member pathways
12.31 CCND2 CDK2 MDM2 TP53
8 12.29 CCND2 CDK2 MDM2 TP53
9 12.22 CCND2 CDK2 MDM2 TP53
10 12.17 CCND2 MDM2 TP53 WT1
11 12.07 CCND2 CDK2 MDM2 TP53
12
Show member pathways
12.06 CCND2 CDK2 MDM2 PDGFRB TP53
13 12.04 CDK2 MDM2 PDGFRB TP53
14 11.91 ABCB1 ABCC1 CCND2 MDM2 PDGFRB TP53
15 11.84 CDK2 MDM2 PDGFRB TP53
16 11.84 CDK2 CYP19A1 ESR1 MDM2 TP53
17
Show member pathways
11.76 CDK2 MDM2 TP53
18
Show member pathways
11.66 CDK2 MDM2 TP53
19 11.65 CDK2 DCK MDM2 TP53
20 11.61 KIT PDGFRB TP53
21 11.55 CDK2 MDM2 TP53
22 11.52 CDK2 MDM2 SMARCB1
23
Show member pathways
11.51 ABCB1 ABCC1 KIT PDGFRB
24 11.4 CDK2 MDM2 TP53
25
Show member pathways
11.31 ABCB1 ABCC1 TP53
26 11.19 CCND2 CDK2 TP53
27 10.83 ABCB1 ABCC1
28 10.8 ABCB1 ABCC1 DCK
29 10.76 ABCB1 ABCC1
30 10.72 ABCB1 TP53
31 10.63 ABCB1 ABCC1
32 10.57 CCND2 CDK2 MDM2 TP53
33 10.15 CYP19A1 ESR1

GO Terms for Uterine Sarcoma

Biological processes related to Uterine Sarcoma according to GeneCards Suite gene sharing:

(show all 15)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 9.93 CCND2 CDK2 KIT MDM2 PDGFRB
2 cell chemotaxis GO:0060326 9.69 ABCC1 KIT PDGFRB
3 regulation of signal transduction by p53 class mediator GO:1901796 9.65 CDK2 MDM2 TP53
4 negative regulation of apoptotic process GO:0043066 9.65 CCND2 MDM2 PDGFRB TP53 WT1
5 cellular response to estrogen stimulus GO:0071391 9.55 ESR1 MDM2
6 DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest GO:0006977 9.54 CDK2 MDM2 TP53
7 replicative senescence GO:0090399 9.52 MME TP53
8 positive regulation of RNA polymerase II transcriptional preinitiation complex assembly GO:0045899 9.49 ESR1 TP53
9 metanephric mesenchyme development GO:0072075 9.46 PDGFRB WT1
10 mitotic G1 DNA damage checkpoint GO:0031571 9.43 CDK2 TP53
11 xenobiotic transport GO:0042908 9.4 ABCB1 ABCC1
12 metanephric S-shaped body morphogenesis GO:0072284 9.32 PDGFRB WT1
13 male gonad development GO:0008584 9.26 ESR1 KIT PDGFRB WT1
14 cellular response to actinomycin D GO:0072717 9.16 MDM2 TP53
15 positive regulation of phospholipase C activity GO:0010863 8.8 ESR1 KIT PDGFRB

Molecular functions related to Uterine Sarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein kinase binding GO:0019901 9.72 CCND2 ESR1 MVP PDGFRB TP53
2 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 9.43 ESR1 KIT PDGFRB
3 p53 binding GO:0002039 9.33 MDM2 SMARCB1 TP53
4 ATP binding GO:0005524 9.23 ABCB1 ABCC1 CDK2 DCK KIT NAV2
5 xenobiotic transmembrane transporting ATPase activity GO:0008559 8.96 ABCB1 ABCC1

Sources for Uterine Sarcoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....